Skip to content

Read-only version: For security reasons, the Research Information System (FIS) has been temporarily replaced by this read-only version. All public content and full texts remain available; login, editing, submission and statistics are not available. Questions: fis@uni-bamberg.de

Home › Publications › The PROVIT Study : Effects of Multispecies Probiotic Add-on Treatment on Metabolomics in Major Depressive Disorder ; A Randomized, Placebo-Controlled Trial

Publication

The PROVIT Study : Effects of Multispecies Probiotic Add-on Treatment on Metabolomics in Major Depressive Disorder ; A Randomized, Placebo-Controlled Trial

Kreuzer, Kathrin; Reiter, Alexandra; Birkl-Töglhofer, Anna-Maria; u. a. (2025): The PROVIT Study : Effects of Multispecies Probiotic Add-on Treatment on Metabolomics in Major Depressive Disorder ; A Randomized, Placebo-Controlled Trial, in: Bamberg: Otto-Friedrich-Universität, S. 1–19.

Details

Faculty/Chair
Faculty/Professorship
Author
Kreuzer, Kathrin; Reiter, Alexandra; Birkl-Töglhofer, Anna-Maria; Dalkner, Nina; Mörkl, Sabrina; Mairinger, Marco; Fleischmann, Eva; Fellendorf, Frederike T.; Platzer, Martina; Lenger, Melanie; ORCID iDFärber, Tanja; Seidl, Matthias; Birner, Armin; Queissner, Robert; Mendel, Lilli-Marie; Maget, Alexander; Kohlhammer-Dohr, Alexandra; Häussl, Alfred; Wagner-Skacel, Jolana; Schöggl, Helmutt; Amberger-Otti, Daniela; Painold, Annamaria; Lahousen-Luxenberger, Theresa; Leitner-Afschar, Brigitta; Haybaeck, Johannes; Habisch, Hansjörg; Madl, Tobias; Reininghaus, Eva; Bengesser, Susanne A.
Publisher Information
Otto-Friedrich-Universität : Bamberg
Year of publication
2025
Source/Other editions
Metabolites, Basel: MDPI, 2022, Jg. 12, Nr. 8, S. 1–19, ISSN: 2218-1989
Year of first publication
2022
Language
English
Licence
URN
Abstract

The gut–brain axis plays a role in major depressive disorder (MDD). Gut-bacterial metabolites are suspected to reduce low-grade inflammation and influence brain function. Nevertheless, randomized, placebo-controlled probiotic intervention studies investigating metabolomic changes in patients with MDD are scarce. The PROVIT study (registered at clinicaltrials.com NCT03300440) aims to close this scientific gap. PROVIT was conducted as a randomized, single-center, double-blind, placebo-controlled multispecies probiotic intervention study in individuals with MDD (n = 57). In addition to clinical assessments, metabolomics analyses (1H Nuclear Magnetic Resonance Spectroscopy) of stool and serum, and microbiome analyses (16S rRNA sequencing) were performed. After 4 weeks of probiotic add-on therapy, no significant changes in serum samples were observed, whereas the probiotic groups’ (n = 28) stool metabolome shifted towards significantly higher concentrations of butyrate, alanine, valine, isoleucine, sarcosine, methylamine, and lysine. Gallic acid was significantly decreased in the probiotic group. In contrast, and as expected, no significant changes resulted in the stool metabolome of the placebo group. Strong correlations between bacterial species and significantly altered stool metabolites were obtained. In summary, the treatment with multispecies probiotics affects the stool metabolomic profile in patients with MDD, which sets the foundation for further elucidation of the mechanistic impact of probiotics on depression.

Keywords
depression
gut–brain-axis
probiotics
metabolomics
NMR spectroscopy
butyrate
randomized controlled trial
DDC Classification
150 Psychology
RVK Classification
CU 1000
Type
Article
URI
Activation date
2025-07-23

Permalink: https://fis.uni-bamberg.de/handle/uniba/108277 · Data as JSON · Cite: BibTeX · RIS

Data as of: 2026-11-15

Restricted read-only access: login, editing and submission are temporarily disabled.